Back to top
more

Nurix Therapeutics (NRIX)

(Real Time Quote from BATS)

$12.78 USD

12.78
186,383

+0.42 (3.40%)

Updated Apr 29, 2024 10:50 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Roche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study

by Zacks Equity Research

Roche's (RHHBY) Columvi, in combination with GemOx, achieves the primary endpoint of overall survival in a late-stage lymphoma study.

ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study

by Zacks Equity Research

ALX Oncology (ALXO) announces positive results from an early to mid-stage study of an investigational combination regimen to treat indolent and aggressive R/R B-NHL.

Nurix (NRIX) Up on Upbeat Initial Data From Phase I Cancer Study

by Zacks Equity Research

Nurix (NRIX) rises on initial findings of clinical responses in the brain for its investigational targeted protein degrader, NX-5948, which is currently under development to treat B cell malignancies.

Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Nurix Therapeutics (NRIX) delivered earnings and revenue surprises of 5% and 13.77%, respectively, for the quarter ended February 2024. Do the numbers hold clues to what lies ahead for the stock?

Vanda (VNDA) Soars 29.2%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Vanda (VNDA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

InflaRx (IFRX) delivered earnings and revenue surprises of -50% and 99.87%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Nurix Therapeutics, Inc. (NRIX) Surges 5.1%: Is This an Indication of Further Gains?

by Zacks Equity Research

Nurix Therapeutics, Inc. (NRIX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Nurix Therapeutics, Inc. (NRIX) delivered earnings and revenue surprises of -50.98% and 50.56%, respectively, for the quarter ended November 2023. Do the numbers hold clues to what lies ahead for the stock?

Incyte (INCY) Lags Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Incyte (INCY) delivered earnings and revenue surprises of -12.40% and 0.74%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Biogen Inc. (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Nurix Therapeutics, Inc. (NRIX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

by Zacks Equity Research

Nurix Therapeutics, Inc. (NRIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Apellis Pharmaceuticals, Inc. (APLS) Soars 14.7%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Apellis Pharmaceuticals, Inc. (APLS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

New Strong Buy Stocks for October 26th

by Zacks Equity Research

GRPN, NRIX, RNLX, ABCL and SMAR have been added to the Zacks Rank #1 (Strong Buy) List on October 26, 2023.

Down -34.9% in 4 Weeks, Here's Why Nurix Therapeutics, Inc. (NRIX) Looks Ripe for a Turnaround

by Zacks Equity Research

Nurix Therapeutics, Inc. (NRIX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Nurix Therapeutics, Inc. (NRIX) delivered earnings and revenue surprises of 1.45% and 7.57%, respectively, for the quarter ended August 2023. Do the numbers hold clues to what lies ahead for the stock?

Reasons to Add Acadia (ACAD) Stock to Your Portfolio Now

by Zacks Equity Research

Here we discuss some reasons why investing in Acadia (ACAD) stock now may turn out to be a more prudent move than ever.

Nurix (NRIX) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

On Nurix's (NRIX) Q3 earnings call, investors will likely focus on updates related to its pipeline candidates for hematologic malignancies and solid tumor indications.

Nurix Therapeutics, Inc. (NRIX) Loses -20.27% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

Nurix Therapeutics, Inc. (NRIX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Nurix Therapeutics, Inc. (NRIX) Loses -19.36% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

Nurix Therapeutics, Inc. (NRIX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Walgreens (WBA) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Continued strategic executions on the United States and the international fronts are likely to drive Walgreens (WBA) Q4 revenues.

Nurix Therapeutics, Inc. (NRIX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Nurix Therapeutics, Inc. (NRIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Nurix Therapeutics, Inc. (NRIX) Crossed Above the 50-Day Moving Average: What That Means for Investors

by Zacks Equity Research

Is it a good or bad thing when a stock surpasses resistance at the 50-day simple moving average?

Nurix Therapeutics, Inc. (NRIX) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Nurix Therapeutics, Inc. (NRIX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Wall Street Analysts Think Nurix Therapeutics, Inc. (NRIX) Could Surge 215.32%: Read This Before Placing a Bet

by Zacks Equity Research

The consensus price target hints at a 215.3% upside potential for Nurix Therapeutics, Inc. (NRIX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Nurix (NRIX) Stock Increases 9% in a Month: Here's Why

by Zacks Equity Research

The upside in Nurix's (NRIX) shares can be attributed to the company's recently signed collaboration with Seagen (SGEN) to develop a new class of medicines for cancer.